Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient

We present a case report of 63-year-old female health care worker who is 15 years status post double lung transplant and six living related donor kidney healthy on chronic immunosuppression regimen including prednisone, mycophenolate, tacrolimus received the SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech BNT162b2) primary series had poor initial humoral response to COVID-19 vaccine, then demonstrated robust, sustained immune against S1 S2 antigens for over seven months after receiving recommended doses, booster dose, without developing or other serious adverse events. Her vaccination indicates effective formation anti-spike T cell memory despite immunosuppression. This provides comprehensive characterization her this series. As effectiveness data updated, as better understanding hybrid immunity emerges, these findings may reassure that recipients SOTs be capable durable responses emerging variants SARS-CoV-2.